Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 19, 2017. The document serves as a transaction notification regarding a specific corporate action involving the company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a specific securities transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Type: Acquisition of ADSs via dividend reinvestment under the US Deferred Performance Share Plan.
- Transaction Date: April 18, 2017.
- Transaction Price: $41.81 per ADS.
- Total Volume: 419.195 ADSs.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
The filing does not provide comparative financial data or discuss material changes in the company's financial position versus prior periods. It reports a routine transaction related to the reinvestment of dividends paid on April 13, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transaction was executed by Mr. D E Troy, SVP & General Counsel, as part of the company's deferred performance share plan.
Investor Verification Points
- Verify the impact of the dividend reinvestment on the total outstanding share count.
- Confirm the dividend payment date of April 13, 2017, referenced in the transaction details.
- Note that this filing is a regulatory disclosure of a specific transaction and does not contain quarterly or annual financial results.